T2 Biosystems, Inc. (TTOO)
Sector: Medical - Diagnostics & Research
Industry: Medical - Diagnostics & Research
T2 Biosystems, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 16, 2026 | 0.0040 | 0.0040 | 0.0004 | 0.0004 | 1,151 |
| Nov 13, 2026 | 0.0004 | 0.0100 | 0.0004 | 0.0100 | 13,909 |
| Nov 12, 2026 | 0.0004 | 0.0090 | 0.0004 | 0.0090 | 749 |
| Nov 11, 2026 | 0.0007 | 0.0100 | 0.0007 | 0.0090 | 133,412 |
| Nov 9, 2026 | 0.0007 | 0.0100 | 0.0007 | 0.0100 | 631 |
| Nov 6, 2026 | 0.0007 | 0.0007 | 0.0002 | 0.0002 | 43,011 |
| Nov 5, 2026 | 0.0020 | 0.0020 | 0.0004 | 0.0004 | 5,001 |
| Nov 4, 2026 | 0.0005 | 0.0005 | 0.0005 | 0.0005 | 1,178 |
| Nov 2, 2026 | 0.0008 | 0.0008 | 0.0008 | 0.0008 | 877 |
| Oct 30, 2026 | 0.0007 | 0.0007 | 0.0007 | 0.0007 | 10,410 |
| Oct 29, 2026 | 0.0007 | 0.0007 | 0.0007 | 0.0007 | 1,701 |
| Oct 28, 2026 | 0.0006 | 0.0006 | 0.0006 | 0.0006 | 1,918 |
| Oct 27, 2026 | 0.0005 | 0.0005 | 0.0005 | 0.0005 | 10,508 |
| Oct 26, 2026 | 0.0006 | 0.0006 | 0.0006 | 0.0006 | 23,672 |
| Oct 23, 2026 | 0.0006 | 0.0006 | 0.0006 | 0.0006 | 142 |
| Oct 22, 2026 | 0.0006 | 0.0006 | 0.0006 | 0.0006 | 311 |
| Oct 21, 2026 | 0.0008 | 0.0008 | 0.0008 | 0.0008 | 1,513 |
| Oct 20, 2026 | 0.0008 | 0.0008 | 0.0008 | 0.0008 | 28,142 |
| Oct 16, 2026 | 0.0007 | 0.0007 | 0.0007 | 0.0007 | 117 |
| Oct 15, 2026 | 0.0007 | 0.0007 | 0.0007 | 0.0007 | 3,582 |
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| CFO | Grant/Award | 180.0K | -- | Nov 4, 2024 | |
| Director | Grant/Award | 25.0K | -- | Nov 4, 2024 | |
| Chief Commercial Officer | Grant/Award | 180.0K | -- | Nov 4, 2024 | |
| Chief Commercial Officer | Grant/Award | 180.0K | -- | Nov 4, 2024 | |
| Director | Grant/Award | 25.0K | -- | Nov 4, 2024 | |
| Director | Grant/Award | 35.0K | -- | Nov 4, 2024 |
| Name | Shares | % | Source |
|---|---|---|---|
Elsbree David B Director | 23 | 0.0% | FORM 4 |
Union Bancaire Privee, UBP SA | 1 | 0.0% | 13F |
Insiders
- Sprague John MCFO
- LIEBMAN SEYMOURDirector
- Giffin Brett A.Chief Commercial Officer
- Adams Laura LeeDirector
- CUMMING JOHN WDirector
- Gibbs Michael TerrenceGeneral Counsel
- Saunders NinfaDirector
- Toft RobinDirector
- Sperzel John J IIISee Remarks
- Elsbree David BDirector
Top institutional holders
T2 Biosystems, Inc. is an in vitro diagnostics company that develops and commercializes innovative diagnostic solutions for global markets.
Its proprietary technology platform enables the rapid detection of pathogens, biomarkers, and other critical abnormalities directly from a wide array of unpurified patient specimens, including whole blood, plasma, serum, saliva, sputum, cerebrospinal fluid, and urine.
The company's commercial offerings include the T2Dx Instrument, a compact bench-top system designed to run various diagnostic assays.
Its current suite of diagnostic tests features T2Candida, a direct-from-blood test that rapidly identifies bloodstream infections leading to sepsis and candidemia; T2Bacteria, another direct-from-blood assay for detecting bacterial pathogens commonly associated with sepsis; T2Resistance, which targets and identifies genes conferring carbapenem resistance; and the T2SARS-CoV-2 panel, developed to detect the SARS-CoV-2 virus.
In addition to its existing products, T2 Biosystems is actively advancing several diagnostic candidates. These include T2Biothreat, aimed at identifying biothreat pathogens; a comprehensive sepsis panel designed to detect bloodstream infections caused by both bacterial and Candida species, along with antibiotic resistance markers; T2Cauris, which offers direct detection of the emerging superbug Candida auris in patient skin, blood, and hospital environmental samples; and T2Lyme, a direct-from-blood test panel specifically engineered for the T2Dx Instrument to identify the bacteria responsible for Lyme disease. T2 Biosystems has also established strategic partnerships, such as its collaboration with Canon U.S. Life Sciences, Inc., to jointly develop a diagnostic test panel for Lyme disease.
The company was founded in 2006 and is headquartered in Lexington, Massachusetts.
based on 28.05M shares outstanding
30d Avg
15.46K
60d Avg
11.03K
90d Avg
11.00K
T2 Biosystems, Inc. (OTC: TTOO) traded at $0.0004 on Nov 16, 2026. 52-week range: $0.0001 to $0.0500. The company is in the Healthcare sector (Medical - Diagnostics & Research).